We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Grant Will Fuel Development of Lab-Grown Mini Tumors for Rare Cancers

Grant Will Fuel Development of Lab-Grown Mini Tumors for Rare Cancers

Grant Will Fuel Development of Lab-Grown Mini Tumors for Rare Cancers

Grant Will Fuel Development of Lab-Grown Mini Tumors for Rare Cancers

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Grant Will Fuel Development of Lab-Grown Mini Tumors for Rare Cancers"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Dr. Alice Soragni of the UCLA Jonsson Comprehensive Cancer Center has received a $2.5 million grant from the National Cancer Institute to develop lab-grown mini tumors that can help identify treatments for rare types of neuroendocrine cancer. The grant is a joint partnership with Dr. Patricia Dahia, a leading expert in neuroendocrine tumors at the University of Texas Health Science Center at San Antonio.

The five-year grant will support Soragni’s efforts into creating miniature tumor organoids models of pheochromocytomas and paragangliomas, two rare catecholamine-secreting, neural crest-derived tumors originating from adrenal or extra adrenal paraganglia. These cancers can be benign or malignant, and it is often impossible to determine who is at risk for progression and metastasis. Even if the cancer doesn’t metastasize, it can have serious symptoms due to the excessive secretion of hormones.

Treatment options for these types of tumors are limited and, despite their genetic diversity, there are few personalized approaches. Advances in this area are dampened by a scarcity of research models to help uncover biological mechanisms that facilitate clinical outcome prediction and reveal molecular vulnerabilities which can be explored for therapeutic purposes.

In collaboration with Dahia, Soragni and her team will create organoid models to replicate the full-functioning, catecholamine-secreting structures of tumors so they can better study their behavior, investigate tumor markers, and drug screen to identify potential new therapies.

“Being able to create models of these rare tumors in the lab can not only help us better understand the molecular and functional diversity of pheochromocytomas and paragangliomas, but also contribute to identifying pathways that can be targeted for therapy,” said Soragni, who is also an assistant professor in the Department of Orthopaedic Surgery at the David Geffen School of Medicine at UCLA and member of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.